The surge in obesity, compounded by COVID-19, has led to increased use of weight loss drugs, notably semaglutide (Wegovy) and tirzepatide (Zepbound) gaining FDA approval. Concerns over adverse effects like pancreatitis and gastroparesis with...
The surge in obesity, compounded by COVID-19, has led to increased use of weight loss drugs, notably semaglutide (Wegovy) and tirzepatide (Zepbound) gaining FDA approval. Concerns over adverse effects like pancreatitis and gastroparesis with...
The surge in obesity, compounded...